Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

This study has been completed.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd. Identifier:
First received: May 25, 2011
Last updated: July 4, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2014
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 24, 2016